Product Name: Blk (386-392) pY389
Product Number: PE-04AIP90
Size: 200 µg      Price:41.00
1 mg      $US82.00
5 mg      194.00
Peptide Name: Blk (386-392) pY389

Product Use: Services as a blocking peptide for use with the BLK-pY389 rabbit polyclonal antibody (Cat. No.: AB-PK543) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y389 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: DSE-pY-TAQ

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1065.97 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Blk - pY389 phosphosite-specific antibody (Cat. No.: AB-PK543)

Scientific Background: Blk is a protein-tyrosine kinase that is a member of the TK group of protein kinases in the Src family. It has been reported that Blk is expressed specifically in the B cell lineage and plays a role in signal transduction pathway that is restricted to B lymphoid cells. However, this kinase has low to reasonably high expression (e.g. skeletal muscle, kidney, thyroid, breast) in most tested human tissues except in the brain and spinal cord where it is poorly expressed. Orthologues of Blk are highly conserved in mammals and birds. Blk is inhibited by phosphorylation at Y501. Blk has been linked with the development of colorectal adenocarcinomas. Stimulation of resting B-lymphocytes with antibodies to surface immunoglobulin (sIgD or sIgM) induces activation of Blk.